An observational study analysing characteristics of neuro-immunological disorders during the COVID-19 pandemic
Latest Information Update: 10 Jun 2021
At a glance
- Drugs Ocrelizumab (Primary) ; Rituximab (Primary) ; Immunotherapies
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy; Multiple sclerosis; Myasthenia gravis; Neuromyelitis optica
- Focus Pharmacodynamics
- 10 Jun 2021 New trial record
- 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology